市場調查報告書

糖尿病性胃輕癱(DGp)- 流行病學預測 2030年

Diabetic Gastroparesis (DGp) - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 601947
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
糖尿病性胃輕癱(DGp)- 流行病學預測 2030年 Diabetic Gastroparesis (DGp) - Epidemiology Forecast - 2030
出版日期: 2020年03月01日內容資訊: 英文 90 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的糖尿病性胃輕癱(DGp)2017年的患病數估算為1,284萬3,848人。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙)的糖尿病性胃輕癱(DGp)市場調查,彙整市場及疾病概要,整體及各國流行病學的預測,性別、各臨床類型、年齡的患病數及診斷數的變化與預測等相關資訊。

目錄

第1章 重要的洞察

第2章 摘要整理

第3章 方法論

第4章 糖尿病性胃輕癱(DGp):患者概要

  • 患者的分佈(實在值)
  • 患者的分佈(預測值)

第5章 疾病背景和概要

  • 簡介
  • 病因和危險因素
  • 症狀
  • 糖尿病性胃輕癱(DGp)的病因
  • 診斷
    • 臨床評分系統
    • 糖尿病性胃輕癱(DGp)的鑑別診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的總患者數

第7章 糖尿病性胃輕癱(DGp)的流行病學預測:各國

  • 美國
    • 假設和根據
    • 糖尿病性胃輕癱(DGp)的總患病數
    • 胃輕癱的患病數:各糖尿病類型
    • 糖尿病性胃輕癱(DGp)的患病數:性別
    • 糖尿病性胃輕癱(DGp)的患病數:各症狀
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第8章 糖尿病性胃輕癱(DGp)的治療和管理

  • 糖尿病性胃輕癱(DGp)臨床管理上共識指南
  • 糖尿病性胃輕癱的管理的演算法
  • 患者歷程

第9章 附錄

  • 書志
  • 報告方法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0274

DelveInsight's 'Diabetic Gastroparesis (DGp)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of DGp in the in 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Diabetic Gastroparesis (DGp) - Disease Understanding

The DelveInsight Diabetic Gastroparesis epidemiology report gives the thorough understanding of the DGp by including details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Diabetic Gastroparesis in the 7MM i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes in which the stomach takes too long to empty its contents (delayed gastric emptying).

Diabetic Gastroparesis (DGp) Epidemiology

The Diabetic Gastroparesis (DGp) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major markets. The epidemiology data for Diabetic Gastroparesis epidemiology are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Diabetic Gastroparesis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of Diabetic Gastroparesis, prevalence of Gastroparesis associated with types of Diabetes Mellitus, prevalence of Diabetic Gastroparesis based on gender, prevalence of symptoms associated with Diabetic Gastroparesis ) scenario of Sickle Cell Disease(DGp) in the 7MM covering covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017-2030.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, Total prevalent population of Diabetic Gastroparesis in 7 MM was observed to be 12,843,848 cases in 2017.

Report Scope

  • The report covers the descriptive overview of Diabetic Gastroparesis, explaining its causes and currently available therapies
  • Comprehensive insight has been provided into the epidemiology of the Diabetic Gastroparesis and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan
  • Additionally, an all-inclusive account of both the current and emerging therapies for Diabetic Gastroparesis are provided, along with assessment of the impact new therapies will have on the current treatment landscape
  • A detailed review of global historical and forecasted Diabetic Gastroparesis market is included in the report, covering drug outreach in 7 MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Diabetic Gastroparesis market

Diabetic Gastroparesis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Diabetic Gastroparesis Epidemiology Segmentation

  • Total prevalent cases of Diabetic Gastroparesis in 7 MM
  • Prevalence of Gastroparesis associated with types of Diabetes Mellitus in 7 MM
  • Prevalence of Diabetic Gastroparesis based on gender in 7 MM
  • Prevalence of symptoms associated with Diabetic Gastroparesis in 7 MM

Table of Contents

1. Key Insights

2. Executive Summary

3. SWOT Analysis for Diabetic Gastroparesis (DGp)

4. Diabetic Gastroparesis Market Overview at a Glance

  • 4.1. Market Share (%) Distribution of Diabetic Gastroparesis in 2017
  • 4.2. Market Share (%) Distribution of Diabetic Gastroparesis in 2030

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Etiology and risk factors
  • 5.3. Signs and Symptoms
  • 5.4. Pathogenesis of Diabetic Gastroparesis
  • 5.5. Diagnosis
    • 5.5.1. Clinical Scoring System
    • 5.5.2. Differential diagnosis of Diabetic Gastroparesis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Prevalent Patient Population of Diabetic Gastroparesis

7. Country Wise-Epidemiology of Diabetic Gastroparesis

  • 7.1. The United States
    • 7.1.1. Assumptions and Rationale
    • 7.1.2. Total Prevalent Cases of Diabetic Gastroparesis in the United States
    • 7.1.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the United States
    • 7.1.4. Prevalence of Diabetic Gastroparesis based on Gender in the United States
    • 7.1.5. Prevalence of Symptoms associated with DGp in the United States
  • 7.2. EU5
    • 7.2.1. Assumptions and Rationale
  • 7.3. Germany
    • 7.3.1. Total Prevalent Cases of Diabetic Gastroparesis in Germany
    • 7.3.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany
    • 7.3.3. Prevalence of Diabetic Gastroparesis based on Gender in Germany
    • 7.3.4. Prevalence of Symptoms associated with DGp in Germany
  • 7.4. France
    • 7.4.1. Total Prevalent Cases of Diabetic Gastroparesis in France
    • 7.4.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France
    • 7.4.3. Prevalence of Diabetic Gastroparesis based on Gender in France
    • 7.4.4. Prevalence of Symptoms associated with DGp in France
  • 7.5. Italy
    • 7.5.1. Total Prevalent Cases of Diabetic Gastroparesis in Italy
    • 7.5.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy
    • 7.5.3. Prevalence of Diabetic Gastroparesis based on Gender in Italy
    • 7.5.4. Prevalence of Symptoms associated with DGp in Italy
  • 7.6. Spain
    • 7.6.1. Total Prevalent Cases of Diabetic Gastroparesis in Spain
    • 7.6.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain
    • 7.6.3. Prevalence of Diabetic Gastroparesis based on Gender in Spain
    • 7.6.4. Prevalence of Symptoms associated with DGp in Spain
  • 7.7. The United Kingdom
    • 7.7.1. Total Prevalent Cases of Diabetic Gastroparesis in the UK
    • 7.7.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK
    • 7.7.3. Prevalence of Diabetic Gastroparesis based on Gender in the UK
    • 7.7.4. Prevalence of Symptoms associated with DGp in the UK
  • 7.8. Japan
    • 7.8.1. Assumptions and Rationale
    • 7.8.2. Total Prevalent Cases of Diabetic Gastroparesis in Japan
    • 7.8.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan
    • 7.8.4. Prevalence of Diabetic Gastroparesis based on Gender in Japan
    • 7.8.5. Prevalence of Symptoms associated with DGp in Japan

8. Treatment and Management of Diabetic Gastroparesis

  • 8.1. Consensus guidelines for the clinical management of diabetic gastroparesis
  • 8.2. Algorithm for the management of diabetic gastroparesis
  • 8.3. Patient Journey for Diabetic Gastroparesis

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

  • Table 1: Prevalent Patient Population of Diabetic Gastroparesis in 7MM (2017-2030)
  • Table 2: Total Prevalent Cases of Diabetic Gastroparesis in the United States (2017-2030)
  • Table 3: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the US (2017-2030)
  • Table 4: Prevalence of Diabetic Gastroparesis based on Gender in the United States (2017-2030)
  • Table 5: Prevalence of Symptoms associated with DGp in the United States (2017-2030)
  • Table 6: Total Prevalent Cases of Diabetic Gastroparesis in Germany (2017-2030)
  • Table 7: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany (2017-2030)
  • Table 8: Prevalence of Diabetic Gastroparesis based on Gender in Germany (2017-2030)
  • Table 9: Prevalence of Symptoms associated with DGp in the Germany (2017-2030)
  • Table 10: Total Prevalent Cases of Diabetic Gastroparesis in France (2017-2030)
  • Table 11: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France (2017-2030)
  • Table 12: Prevalence of Diabetic Gastroparesis based on Gender in France (2017-2030)
  • Table 13: Prevalence of Symptoms associated with DGp in France (2017-2030)
  • Table 14: Total Prevalent Cases of Diabetic Gastroparesis in Italy (2017-2030)
  • Table 15: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy (2017-2030)
  • Table 16: Prevalence of Diabetic Gastroparesis based on Gender in Italy (2017-2030)
  • Table 17: Prevalence of Symptoms associated with DGp in Italy (2017-2030)
  • Table 18: Total Prevalent Cases of Diabetic Gastroparesis in Spain (2017-2030)
  • Table 19: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain (2017-2030)
  • Table 20: Prevalence of Diabetic Gastroparesis based on Gender in Spain (2017-2030)
  • Table 21: Prevalence of Symptoms associated with DGp in Spain (2017-2030)
  • Table 22: Total Prevalent Cases of Diabetic Gastroparesis in the UK (2017-2030)
  • Table 23: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK (2017-2030)
  • Table 24: Prevalence of Diabetic Gastroparesis based on Gender in the UK (2017-2030)
  • Table 25: Prevalence of Symptoms associated with DGp in the UK (2017-2030)
  • Table 26: Total Prevalent Cases of Diabetic Gastroparesis in Japan (2017-2030)
  • Table 27: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan (2017-2030)
  • Table 28: Prevalence of Diabetic Gastroparesis based on Gender in Japan (2017-2030)
  • Table 29: Prevalence of Symptoms associated with DGp in Japan (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Glucose and gastric emptying: bidirectional relationship
  • Figure 3: Pathophysiology of diabetic gastroparesis
  • Figure 4: Diagnosis algorithm for Diabetic Gastroparesis
  • Figure 5: Prevalent Patient Population of Diabetic Gastroparesis in 7MM (2017-2030)
  • Figure 6: Total Prevalent Cases of Diabetic Gastroparesis in the United States (2017-2030)
  • Figure 7: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the US (2017-2030)
  • Figure 8: Prevalence of Diabetic Gastroparesis based on Gender in the United States (2017-2030)
  • Figure 9: Prevalence of Symptoms associated with DGp in the United States (2017-2030)
  • Figure 10: Total Prevalent Cases of Diabetic Gastroparesis in the Germany (2017-2030)
  • Figure 11: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany (2017-2030)
  • Figure 12: Prevalence of Diabetic Gastroparesis based on Gender in Germany (2017-2030)
  • Figure 13: Prevalence of Symptoms associated with DGp in Germany (2017-2030)
  • Figure 14: Total Prevalent Cases of Diabetic Gastroparesis in France (2017-2030)
  • Figure 15: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France (2017-2030)
  • Figure 16: Prevalence of Diabetic Gastroparesis based on Gender in France (2017-2030)
  • Figure 17: Prevalence of Symptoms associated with DGp in France (2017-2030)
  • Figure 18: Total Prevalent Cases of Diabetic Gastroparesis in Italy (2017-2030)
  • Figure 19: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy (2017-2030)
  • Figure 20: Prevalence of Diabetic Gastroparesis based on Gender in Italy (2017-2030)
  • Figure 21: Prevalence of Symptoms associated with DGp in Italy (2017-2030)
  • Figure 22: Total Prevalent Cases of Diabetic Gastroparesis in Spain (2017-2030)
  • Figure 23: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain (2017-2030)
  • Figure 24: Prevalence of Diabetic Gastroparesis based on Gender in Spain (2017-2030)
  • Figure 25: Prevalence of Symptoms associated with DGp in Spain (2017-2030)
  • Figure 26: Total Prevalent Cases of Diabetic Gastroparesis in the UK (2017-2030)
  • Figure 27: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK (2017-2030)
  • Figure 28: Prevalence of Diabetic Gastroparesis based on Gender in the UK (2017-2030)
  • Figure 29: Prevalence of Symptoms associated with DGp in the UK (2017-2030)
  • Figure 30: Total Prevalent Cases of Diabetic Gastroparesis in Japan (2017-2030)
  • Figure 31: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan (2017-2030)
  • Figure 32: Prevalence of Diabetic Gastroparesis based on Gender in Japan (2017-2030)
  • Figure 33: Prevalence of Symptoms associated with DGp in Japan (2017-2030)
  • Figure 34: Suggested therapeutic options for gastroparesis
  • Figure 35: Algorithm for the management of diabetic gastroparesis.
  • Figure 36: Patient Journey for DG
  • Figure 37: Unmet Needs of Diabetic Gastroparesis